Paper
The industry problem is not just about rates. It is also about a very large unresolved stock.
How large is the industry-specific disclosure gap inside the live ClinicalTrials.gov registry? We analysed the March 29, 2026 full-registry snapshot, focusing on 128,464 industry-linked studies and 87,296 closed interventional industry studies. We derived sponsor-level omission flags for missing results, missing actual dates, missing actual enrollment, missing IPD statements, missing publication links, and missing detailed descriptions, while preserving sponsor-level counts so absolute backlog and rate-based silence could be read together across named firms globally. Among eligible older closed interventional industry studies, 58.1 percent still had no posted results, leaving 44,007 unresolved two-year no-results records in the industry bucket alone. The biggest absolute backlogs sat with GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Sanofi, and Pfizer, while several smaller sponsors exceeded 95 percent on the same rate metric. Industry records were also structurally sparse, with 63.2 percent lacking IPD statements, 66.6 percent lacking publication links, and 53.8 percent lacking detailed descriptions. These estimates identify registry-visible non-disclosure rather than adjudicated legal breach.